Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
143 hedge funds and large institutions have $1.86B invested in Clovis Oncology, Inc. in 2014 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 57 increasing their positions, 41 reducing their positions, and 23 closing their positions.
42% more capital invested
Capital invested by funds: $1.31B → $1.86B (+$551M)
39% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 41
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
4% more funds holding
Funds holding: 138 → 143 (+5)
17% less call options, than puts
Call options by funds: $22.6M | Put options by funds: $27.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$49.7M |
| 2 |
O
OrbiMed
New York
|
+$37.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$29.1M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$26.5M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$65.5M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$12M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.2M |
| 4 |
CCI
Columbus Circle Investors
|
-$8.72M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$8.17M |
CLVS Hedge Fund Activity: Q4 2014 in Review
143 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q4 2014, worth a combined $1.86B — up 42% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CLVS positions and 23 closed out — a net gain of 6 holders — while 57 added to existing stakes and 41 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $49.7M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $65.5M sold.
- 143 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q4 2014, up from 138 in Q3 2014.
- Funds reported $1.86B of Clovis Oncology, Inc. stock for Q4 2014, up 42% quarter-over-quarter.
- 29 funds opened new Clovis Oncology, Inc. positions in Q4 2014 and 23 closed out, a net change of +6 holders.
- The largest Clovis Oncology, Inc. buyer in Q4 2014 was T. Rowe Price Associates, an estimated $49.7M added.
- The largest Clovis Oncology, Inc. seller in Q4 2014 was Adage Capital Partners, an estimated $65.5M sold.
Based on aggregated 13F filings for Q4 2014.